“We’re honored to be recognized among this group of health technology pioneers, but the real reward comes from helping our customers develop new medical treatments for the patients who need them,” said James Corrigan, President & CEO, ERT.
PHILADELPHIA (PRWEB) January 23, 2018
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that it has been named to the Journal of mHealth’s annual Global Digital Health 100, an international benchmark for mobile, digital and connected technologies in healthcare.
The Global Digital Health 100 is one of the HealthTech industry’s foremost technology award programs. Celebrating innovation and entrepreneurship, it recognizes the health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.
"ERT has consistently demonstrated true innovation through its ground-breaking products and services, which are enabling long term healthcare programs and transforming the clinical trial process,” said Matthew Driver, Managing Editor, Journal of mHealth.
ERT’s position on the Global Digital Health 100 list is fueled by the company’s digital solutions, which are used by researchers, patients, caregivers and healthcare professionals to support real world and clinical research programs. The company’s award-winning offerings include patient support programs to help patients better manage their disease and set goals for themselves, communities where patients can share their experiences with each other and mobile apps that enhance post-approval data collection programs. Other digital solutions include electronic Clinical Outcome Assessment (eCOA) systems that collect high-quality, regulatory compliant patient data anytime, anywhere via browser, tablet or smartphone as well as voice assistance technology that simplifies clinical trial participation to keep patients engaged, enrolled and compliant with the study protocol.
“We’re honored to be recognized among this group of health technology pioneers, but the real reward comes from helping our customers develop new medical treatments for the patients who need them,” said James Corrigan, President & CEO, ERT. “We are committed to delivering solutions that accelerate new medical product development and will continue exploring how novel technologies can be leveraged to support patients throughout their healthcare journeys.”
For more information on ERT, visit ert.com.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs and CROs have relied on ERT solutions in 10,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.